Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Int J Hematol Retrieve available abstracts of 121 articles: HTML format

Single Articles

October 2025
1. AKAHANE K, Kasai S, Tamai M, Sugita Y, et al
   Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.
   Int J Hematol. 2025;122:611-615.
   PubMed     Abstract available
   
   
   September 2025
2. TOMINAGA R, Fujiwara SI, Honda S, Yokoyama D, et al
   Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia.
   Int J Hematol. 2025 Sep 18. doi: 10.1007/s12185-025-04070.
   PubMed     Abstract available
   
   
   
3. HAN W, Wang S, Zhang M, Fu S, et al
   Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.
   Int J Hematol. 2025 Sep 10. doi: 10.1007/s12185-025-04064.
   PubMed     Abstract available
   
   
   
4. TAKAHASHI H, Tanaka S, Yuza Y, Iijima-Yamashita Y, et al
   Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
   Int J Hematol. 2025 Sep 4. doi: 10.1007/s12185-025-04060.
   PubMed     Abstract available
   
   
   
5. ONO K, Horiguchi H, Iyama S, Sato K, et al
   Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms.
   Int J Hematol. 2025;122:400-412.
   PubMed     Abstract available
   
   
   August 2025
6. LIU ZY, Yan ZY, Li JF, Zhu YM, et al
   Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.
   Int J Hematol. 2025;122:295-300.
   PubMed     Abstract available
   
   
   July 2025
7. HAYASHINO K, Mochizuki N, Kawatsuki A, Fujiwara Y, et al
   Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.
   Int J Hematol. 2025 Jul 22. doi: 10.1007/s12185-025-04041.
   PubMed     Abstract available
   
   
   
8. MAKISHIMA H, Mikasa T, Isogaya K, Miyamoto T, et al
   Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.
   Int J Hematol. 2025;122:57-65.
   PubMed     Abstract available
   
   
   June 2025
9. UYGUN A, Albayrak C, Ozgen U, Dincer OS, et al
   The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
   Int J Hematol. 2025 Jun 30. doi: 10.1007/s12185-025-04027.
   PubMed     Abstract available
   
   
   
10. IMI T, Asakura H, Sato K, Yamada S, et al
    Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
    Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020.
    PubMed     Abstract available
    
    
    
11. NOSAKA K, Fukushima T
    JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9-adult T-cell leukemia-lymphoma (ATL).
    Int J Hematol. 2025 Jun 4. doi: 10.1007/s12185-025-04011.
    PubMed    
    
    
    
12. MASUDA Y, Sadato D, Toya T, Hosoda Y, et al
    Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.
    Int J Hematol. 2025;121:820-832.
    PubMed     Abstract available
    
    
    May 2025
13. TAKAHASHI N, Kikushige Y, Nakamae H, Goto T, et al
    Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.
    Int J Hematol. 2025 May 26. doi: 10.1007/s12185-025-04014.
    PubMed     Abstract available
    
    
    
14. KONISHI H, Tachibana T, Arai S, Izumi A, et al
    Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Int J Hematol. 2025 May 23. doi: 10.1007/s12185-025-04009.
    PubMed     Abstract available
    
    
    
15. IKEDA J, Shiba N, Kato S, Kunimoto H, et al
    Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.
    Int J Hematol. 2025;121:694-705.
    PubMed     Abstract available
    
    
    
16. SAKURAI Y, Yanagimachi M, Ito M, Hirose A, et al
    A case of acute promyelocytic leukemia complicated by mitochondrial disease.
    Int J Hematol. 2025 May 1. doi: 10.1007/s12185-025-03992.
    PubMed     Abstract available
    
    
    April 2025
17. OKA S, Akagi Y, Mituyoshi T, Ono K, et al
    Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient.
    Int J Hematol. 2025 Apr 29. doi: 10.1007/s12185-025-03994.
    PubMed     Abstract available
    
    
    
18. ITO T, Kamimura T, Kiguchi T, Kato K, et al
    Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
    Int J Hematol. 2025 Apr 11. doi: 10.1007/s12185-025-03978.
    PubMed    
    
    
    
19. NGUYEN T, Harama D, Tamai M, Kagami K, et al
    Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation.
    Int J Hematol. 2025 Apr 10. doi: 10.1007/s12185-025-03981.
    PubMed     Abstract available
    
    
    
20. IZUTSU K, Ishikawa T, Shimada K, Kubo K, et al
    Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenstrom macroglobulinemia and CLL/SLL.
    Int J Hematol. 2025;121:483-493.
    PubMed     Abstract available
    
    
    
21. TOKUSHIGE J, Taoka K, Nishikawa M, Jona M, et al
    Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria.
    Int J Hematol. 2025;121:543-546.
    PubMed     Abstract available
    
    
    
22. NISHIWAKI S, Terakura S, Morishita T, Goto T, et al
    Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.
    Int J Hematol. 2025;121:494-503.
    PubMed     Abstract available
    
    
    March 2025
23. KOH K, Kosaka Y, Okamoto Y, Maeda N, et al
    Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia.
    Int J Hematol. 2025 Mar 31. doi: 10.1007/s12185-025-03976.
    PubMed     Abstract available
    
    
    
24. NISHIMURA A, Tamura A, Fujikawa T, Inoue S, et al
    KMT2A-CBL fusion gene in the first reported case of T-cell acute lymphoblastic leukemia associated with Wiedemann-Steiner syndrome.
    Int J Hematol. 2025 Mar 28. doi: 10.1007/s12185-025-03975.
    PubMed     Abstract available
    
    
    
25. YOSHIKAWA T, Ishida H, Watanabe A, Yuza Y, et al
    Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.
    Int J Hematol. 2025 Mar 15. doi: 10.1007/s12185-025-03953.
    PubMed     Abstract available
    
    
    
26. KAMIUNTEN A, Kameda T, Sekine M, Kawano H, et al
    Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.
    Int J Hematol. 2025 Mar 11. doi: 10.1007/s12185-025-03963.
    PubMed     Abstract available
    
    
    
27. TAKAMATSU Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Int J Hematol. 2025 Mar 1. doi: 10.1007/s12185-025-03914.
    PubMed    
    
    
    February 2025
28. ABUMIYA M, Saito A, Fujioka Y, Miura M, et al
    Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.
    Int J Hematol. 2025 Feb 25. doi: 10.1007/s12185-025-03954.
    PubMed     Abstract available
    
    
    
29. ISHII S, Arakawa Y, Ishii H, Yokoyama K, et al
    A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation.
    Int J Hematol. 2025 Feb 20. doi: 10.1007/s12185-025-03944.
    PubMed     Abstract available
    
    
    
30. MATSUMOTO Y, Kato D, Muramatsu A, Sugitani M, et al
    Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations.
    Int J Hematol. 2025 Feb 19. doi: 10.1007/s12185-025-03938.
    PubMed     Abstract available
    
    
    January 2025
31. FENG LS, Li HY, Tang A, Xu ML, et al
    Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.
    Int J Hematol. 2025 Jan 23. doi: 10.1007/s12185-025-03915.
    PubMed     Abstract available
    
    
    
32. MIYAZAKI Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS).
    Int J Hematol. 2025 Jan 14. doi: 10.1007/s12185-024-03906.
    PubMed    
    
    
    
33. MIYAZAKI T, Uno S, Fujimori H, Motegi Y, et al
    Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.
    Int J Hematol. 2025;121:79-88.
    PubMed     Abstract available
    
    
    
34. SAWA M, Miyamoto T, Kim HJ, Hiramatsu Y, et al
    A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.
    Int J Hematol. 2025;121:56-67.
    PubMed     Abstract available
    
    
    December 2024
35. CHIRIAC R
    Pseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia.
    Int J Hematol. 2024 Dec 30. doi: 10.1007/s12185-024-03910.
    PubMed    
    
    
    
36. UTSUNOMIYA A, Yasunaga JI, Tabuchi T, Nakano N, et al
    A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.
    Int J Hematol. 2024 Dec 25. doi: 10.1007/s12185-024-03901.
    PubMed     Abstract available
    
    
    
37. FUJITA H
    Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03908.
    PubMed    
    
    
    
38. MAEDA Y
    Correction: JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03907.
    PubMed    
    
    
    
39. ARAI H, Hosono N, Chi S, Fukushima K, et al
    A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.
    Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895.
    PubMed     Abstract available
    
    
    
40. KOHSO A, Toyoda H, Hanaki R, Niwa K, et al
    Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.
    Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890.
    PubMed     Abstract available
    
    
    
41. INAMURA J, Taketani T, Mochida M, Goto T, et al
    Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.
    Int J Hematol. 2024 Dec 4. doi: 10.1007/s12185-024-03881.
    PubMed     Abstract available
    
    
    
42. SHIMONODAN H, Sakaguchi K, Ishihara T, Okamoto Y, et al
    Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial.
    Int J Hematol. 2024;120:725-734.
    PubMed     Abstract available
    
    
    November 2024
43. TAKAHASHI N, Takenaka K, Iriyama N, Kirito K, et al
    JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03865.
    PubMed    
    
    
    
44. MUTA T, Masamoto Y, Yamamoto G, Kurahashi S, et al
    Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03875.
    PubMed     Abstract available
    
    
    
45. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.
    Int J Hematol. 2024 Nov 25. doi: 10.1007/s12185-024-03880.
    PubMed     Abstract available
    
    
    
46. ISHII Y, Fujisawa S, Miyazaki T, Nakajima Y, et al
    Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.
    Int J Hematol. 2024 Nov 19. doi: 10.1007/s12185-024-03873.
    PubMed     Abstract available
    
    
    
47. SABURI M, Nishikawa T, Kawano K, Ohtsuka E, et al
    Successful complete remission after induction therapy with CPX-351 for acute myeloid leukemia with myelodysplasia-related changes accompanied by double-minute chromosomes and MYC gene amplification.
    Int J Hematol. 2024 Nov 11. doi: 10.1007/s12185-024-03876.
    PubMed    
    
    
    
48. NAKA R, Shimomura Y, Miura M, Nagai Y, et al
    Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.
    Int J Hematol. 2024 Nov 7. doi: 10.1007/s12185-024-03869.
    PubMed     Abstract available
    
    
    
49. ISHIKAWA Y
    Recent progress in AML with recurrent genetic abnormalities.
    Int J Hematol. 2024;120:525-527.
    PubMed     Abstract available
    
    
    
50. SUGIURA H, Ishikawa T, Kuroi T, Okamoto S, et al
    Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples.
    Int J Hematol. 2024;120:594-600.
    PubMed     Abstract available
    
    
    
51. ISHIKAWA Y, Ushijima Y, Kiyoi H
    Recent advances in AML with mutated NPM1.
    Int J Hematol. 2024;120:556-565.
    PubMed     Abstract available
    
    
    
52. KENNEDY VE, Smith CC
    FLT3 targeting in the modern era: from clonal selection to combination therapies.
    Int J Hematol. 2024;120:528-540.
    PubMed     Abstract available
    
    
    October 2024
53. OUCHI F, Shingai N, Najima Y, Sadato D, et al
    Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.
    Int J Hematol. 2024 Oct 26. doi: 10.1007/s12185-024-03863.
    PubMed     Abstract available
    
    
    
54. HASHIMOTO M, Kato T, Yokota K, Sakamoto H, et al
    Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.
    Int J Hematol. 2024 Oct 10. doi: 10.1007/s12185-024-03857.
    PubMed     Abstract available
    
    
    
55. CHIRIAC R
    Therapy-related acute myeloid leukemia with inv(16)(p13.1q22).
    Int J Hematol. 2024 Oct 8. doi: 10.1007/s12185-024-03858.
    PubMed    
    
    
    
56. URRUTIA S, Takahashi K
    Precision medicine in AML: overcoming resistance.
    Int J Hematol. 2024;120:439-454.
    PubMed     Abstract available
    
    
    
57. YOSHIMARU R, Minami Y
    Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML.
    Int J Hematol. 2024;120:512-514.
    PubMed     Abstract available
    
    
    
58. SAITO S, Nakazawa Y
    CAR-T cell therapy in AML: recent progress and future perspectives.
    Int J Hematol. 2024;120:455-466.
    PubMed     Abstract available
    
    
    September 2024
59. KINOSHITA M, Saito Y, Otani K, Uehara Y, et al
    Mitochondrial dynamics as a potential therapeutic target in acute myeloid leukemia.
    Int J Hematol. 2024 Sep 16. doi: 10.1007/s12185-024-03843.
    PubMed     Abstract available
    
    
    
60. HATTA Y, Izutsu K, Onizuka M, Dobashi N, et al
    JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL.
    Int J Hematol. 2024 Sep 6. doi: 10.1007/s12185-024-03836.
    PubMed    
    
    
    
61. YAMAGUCHI H
    Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.
    Int J Hematol. 2024 Sep 3. doi: 10.1007/s12185-024-03837.
    PubMed     Abstract available
    
    
    
62. MINAMI Y, Doki N, Matsuoka H, Yokota T, et al
    Asciminib in Patients With CML-CP Previously Treated With >/= 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Int J Hematol. 2024;120:305-313.
    PubMed     Abstract available
    
    
    
63. SUZUKI K, Koyama D, Oka Y, Sato Y, et al
    Myeloid sarcoma with plasmacytoid dendritic cell-like proliferation associated with IKZF1, ETV6 and DNMT3A mutations.
    Int J Hematol. 2024;120:382-388.
    PubMed     Abstract available
    
    
    August 2024
64. NISHIJIMA M, Ido K, Okayama Y, Okamura H, et al
    A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion.
    Int J Hematol. 2024 Aug 30. doi: 10.1007/s12185-024-03839.
    PubMed     Abstract available
    
    
    
65. GOTO H, Kada A, Ogawa C, Nishiuchi R, et al
    Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group.
    Int J Hematol. 2024 Aug 27. doi: 10.1007/s12185-024-03838.
    PubMed     Abstract available
    
    
    
66. ITO T, Kamimura T, Kiguchi T, Kato K, et al
    Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
    Int J Hematol. 2024 Aug 21. doi: 10.1007/s12185-024-03832.
    PubMed     Abstract available
    
    
    
67. NAGATA Y
    Molecular pathophysiology of germline mutations in acute myeloid leukemia.
    Int J Hematol. 2024 Aug 16. doi: 10.1007/s12185-024-03824.
    PubMed     Abstract available
    
    
    
68. URESHINO H, Takahashi N, Ikezoe T, Kameoka Y, et al
    A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).
    Int J Hematol. 2024 Aug 13. doi: 10.1007/s12185-024-03830.
    PubMed     Abstract available
    
    
    
69. OYA S, Ozawa H, Nakamura T, Mori A, et al
    CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
    Int J Hematol. 2024;120:194-202.
    PubMed     Abstract available
    
    
    
70. LU Y, Ma WB, Ren GM, Li YT, et al
    GPS2 promotes erythroid differentiation in K562 erythroleukemia cells primarily via NCOR1.
    Int J Hematol. 2024;120:157-166.
    PubMed     Abstract available
    
    
    
71. ZHANG W, Li J, Yamamoto K, Goyama S, et al
    Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency.
    Int J Hematol. 2024;120:186-193.
    PubMed     Abstract available
    
    
    July 2024
72. IKEDA S, Suzuki M, Tsunoda S, Ohta M, et al
    Dynamic changes in femoral bone marrow MRI in patients with chronic myelogenous leukemia.
    Int J Hematol. 2024 Jul 15. doi: 10.1007/s12185-024-03819.
    PubMed    
    
    
    
73. KUROSAWA S, Nakazato T
    Immunohistochemical differentiation of extramedullary acute myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm.
    Int J Hematol. 2024 Jul 10. doi: 10.1007/s12185-024-03817.
    PubMed    
    
    
    
74. OYA S, Ozawa H, Morishige S, Maehiro Y, et al
    High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Int J Hematol. 2024 Jul 4. doi: 10.1007/s12185-024-03814.
    PubMed     Abstract available
    
    
    
75. SAJIKI D, Yoshida N, Muramatsu H, Sakaguchi K, et al
    Clinical features of immature leukemias in children.
    Int J Hematol. 2024;120:117-127.
    PubMed     Abstract available
    
    
    May 2024
76. GONZALEZ-MANCERA MS, Lopategui J, Hoffman D, Kitahara S, et al
    B-cell prolymphocytic leukemia: an enduring bona fide entity.
    Int J Hematol. 2024 May 26. doi: 10.1007/s12185-024-03774.
    PubMed     Abstract available
    
    
    
77. ARAI S, Tachibana T, Izumi A, Takeda T, et al
    WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03795.
    PubMed     Abstract available
    
    
    
78. SHI X, Feng M, Nakada D
    Metabolic dependencies of acute myeloid leukemia stem cells.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03789.
    PubMed     Abstract available
    
    
    
79. AKIYAMA H, Kantarjian H, Jabbour E, Issa G, et al
    Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03787.
    PubMed     Abstract available
    
    
    
80. KAITO Y, Imai Y
    Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
    Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778.
    PubMed     Abstract available
    
    
    
81. ITO M, Fukushima N
    Faggot cells observed in a patient with myelodysplastic syndrome with increased blasts.
    Int J Hematol. 2024;119:476-478.
    PubMed    
    
    
    April 2024
82. KATSUKI K, Tachibana T, Izumi A, Kim K, et al
    Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
    Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775.
    PubMed     Abstract available
    
    
    
83. TIEN FM, Hou HA
    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
    Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773.
    PubMed     Abstract available
    
    
    
84. FUJITA H
    JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
    PubMed    
    
    
    
85. IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
    Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
    Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
    PubMed     Abstract available
    
    
    
86. TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al
    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752.
    PubMed     Abstract available
    
    
    
87. NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
    Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
    Int J Hematol. 2024;119:426-431.
    PubMed     Abstract available
    
    
    March 2024
88. USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
    A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
    PubMed     Abstract available
    
    
    
89. XU J, Zong S, Sheng T, Zheng J, et al
    Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
    PubMed     Abstract available
    
    
    
90. IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al
    Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia.
    Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748.
    PubMed     Abstract available
    
    
    
91. TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al
    Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741.
    PubMed     Abstract available
    
    
    
92. KAWAKAMI Y, Imamura M, Imai C
    Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756.
    PubMed    
    
    
    
93. MAEDA Y
    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
    PubMed    
    
    
    
94. SANO H, Fukushima K, Yano M, Osone S, et al
    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
    Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
    PubMed     Abstract available
    
    
    
95. XUE S, Sun HP, Huang XB, Chen X, et al
    Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
    Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729.
    PubMed     Abstract available
    
    
    
96. AN K, He Y, Tang Y, Gu X, et al
    Histiocytic sarcoma following CAR T-cell therapy: a case report.
    Int J Hematol. 2024;119:338-341.
    PubMed     Abstract available
    
    
    February 2024
97. SHIOZAWA Y, Fujita S, Nannya Y, Ogawa S, et al
    First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724.
    PubMed     Abstract available
    
    
    
98. CHOED-AMPHAI C, Khorana J, Sathitsamitphong L, Natesirinilkul R, et al
    Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725.
    PubMed     Abstract available
    
    
    
99. YOKOYAMA Y
    Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.
    Int J Hematol. 2024 Feb 22. doi: 10.1007/s12185-023-03696.
    PubMed     Abstract available
    
    
    
100. HISADA Y
     Dysregulated hemostasis in acute promyelocytic leukemia.
     Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708.
     PubMed     Abstract available
     
     
     
101. YANAGI M, Mori M, Honda M, Mitani Y, et al
     Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
     Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701.
     PubMed     Abstract available
     
     
     
102. MARUYAMA D, Omi A, Nomura F, Touma T, et al
     Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
     Int J Hematol. 2024;119:146-155.
     PubMed     Abstract available
     
     
     
103. SCHALK E, Pelz AF
     Auer rods in mature granulocytes in peripheral blood.
     Int J Hematol. 2024;119:105-106.
     PubMed    
     
     
     
104. USUKI K, Ohtake S, Honda S, Matsuda M, et al
     Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
     Int J Hematol. 2024;119:130-145.
     PubMed     Abstract available
     
     
     January 2024
105. UEKI H, Ogawa C, Goto H, Nishi M, et al
     TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
     Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710.
     PubMed     Abstract available
     
     
     
106. OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al
     Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission.
     Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707.
     PubMed     Abstract available
     
     
     
107. KATO K, Takagi S, Takano H, Tsunoda S, et al
     A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
     Int J Hematol. 2024 Jan 18. doi: 10.1007/s12185-023-03691.
     PubMed     Abstract available
     
     
     
108. OYAKE M, Hirakuni Y, Hirano N, Suenobu S, et al
     Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute lymphoblastic leukemia without peripheral blasts.
     Int J Hematol. 2024 Jan 3. doi: 10.1007/s12185-023-03697.
     PubMed    
     
     
     
109. USUKI K, Ohtake S, Honda S, Matsuda M, et al
     Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
     Int J Hematol. 2024;119:24-38.
     PubMed     Abstract available
     
     
     
110. ITO M, Fukushima N, Fujii T, Numata M, et al
     Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2024;119:80-87.
     PubMed     Abstract available
     
     
     December 2023
111. MAKITA S, Ota S, Mishima Y, Usuki K, et al
     Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
     Int J Hematol. 2023 Dec 27. doi: 10.1007/s12185-023-03689.
     PubMed     Abstract available
     
     
     
112. ZHAO B, Yin J, Ding L, Luo J, et al
     SPAG6 regulates cell proliferation and apoptosis via TGF-beta/Smad signal pathway in adult B-cell acute lymphoblastic leukemia.
     Int J Hematol. 2023 Dec 26. doi: 10.1007/s12185-023-03684.
     PubMed     Abstract available
     
     
     
113. NUKUI J, Tachibana T, Miyazaki T, Tanaka M, et al
     Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688.
     PubMed     Abstract available
     
     
     
114. TAKEYASU S, Morita K, Saito S, Toho M, et al
     Myeloid sarcoma and pathological fracture: a case report and review of literature.
     Int J Hematol. 2023;118:745-750.
     PubMed     Abstract available
     
     
     
115. MIKI K, Ogasawara R, Sugimura S, Sugita J, et al
     A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation.
     Int J Hematol. 2023;118:766-771.
     PubMed     Abstract available
     
     
     November 2023
116. SHIOMI I, Nakako S, Nakane T, Ogawa Y, et al
     Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
     Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678.
     PubMed     Abstract available
     
     
     
117. SAKAI Y, Ikawa Y, Takenaka M, Noguchi K, et al
     Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis.
     Int J Hematol. 2023 Nov 21. doi: 10.1007/s12185-023-03675.
     PubMed     Abstract available
     
     
     October 2023
118. FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al
     A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.
     Int J Hematol. 2023;118:472-476.
     PubMed     Abstract available
     
     
     
119. UNO S, Motegi Y, Minehata K, Aoki Y, et al
     Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
     Int J Hematol. 2023;118:432-442.
     PubMed     Abstract available
     
     
     September 2023
120. ZHANG A, Liu L, Zong S, Chang L, et al
     Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 x 10(9)/L.
     Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665.
     PubMed     Abstract available
     
     
     
121. HARA R, Machida S, Hashimoto N, Ogiya D, et al
     Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
     Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.